This year NICE has been updating the clinical guideline on the management of type 2 diabetes. Boehringer Ingelheim has welcomed and contributed to NICE’s extensive consultations on the draft guideline and acknowledges that NICE has now addressed many of the issues seen in the initial draft. The current updated guideline published this month[i] now reflects a much more pragmatic approach to patient centred care and is representative of current glucose lowering therapies. I am pleased that the new clinical guideline will help to improve the care of patients living with type 2 diabetes.
Since 1996, the number of people living with diabetes in England has more than doubled to 3.2 million. [ii] It is estimated that 2.7 million people are currently diagnosed with diabetes and a further 500,000 people have the disease but do not know it.ii If trends continue, this number will rise to 4 million people by 2025.ii Poorly managed diabetes is the cause of 20,000 early deaths per year[iii] and diabetes accounts for around 10 percent of the annual NHS budget, or about £10 billion a year.ii
As documented in our health policy briefing which I helped to launch in Parliament earlier this year,[iv] Boehringer Ingelheim has been calling for all relevant diabetes guidelines to adopt an individualised approach to patient care that enables patient-centred prescribing in line with the principles of medicine optimisation. Previous draft guidelines have appeared to be heavily focussed on short-term cost efficiencies and failed to acknowledge the importance to patients of hypoglycaemic episodes and weight gain associated with type 2 diabetes.
I am pleased to see that the new NICE guideline does favour a more individualised approach to patient care. This will help to ensure that medicines are tailored to the individuals’ needs and circumstances, and that patients are offered the effective treatments they deserve.
What do you think about the new guideline on the management of type 2 diabetes? Please leave a comment here and tell me what you think.
Professor Klaus Dugi, Managing Director / Medical Director Boehringer Ingelheim UK & Ireland
[i] NICE (2015) Type 2 diabetes in adults: management
[ii] Diabetes UK (2014) State of The Nation: Challenges for 2015 and beyond
[iii] HSCIC (2012) National Diabetes Audit 2011-2012. Report 2:Complications and Mortality
[iv] Boehringer Ingelheim (2015) Health Policy Briefing